The MTA3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt lymphoma Raji B lymphocyte line. These cells feature targeted disruption of the MTA3 gene, which encodes a core subunit of the nucleosome remodeling and deacetylase (NuRD) complex. The polyclonal population consists of a heterogeneous pool of edited cells, enabling functional studies of MTA3-dependent transcriptional silencing within a physiologically relevant germinal center B-cell context without clonal isolation artifacts.
Raji cells are Epstein-Barr virus (EBV)-positive B lymphocytes originally isolated from a Burkitt lymphoma patient. This line retains features of germinal center B cells, including expression of key regulators such as BCL6 and surface markers characteristic of this differentiation stage. As a widely used model for B-cell lymphomas and immunological studies, Raji cells provide a robust platform for investigating the molecular mechanisms governing germinal center biology and lymphomagenesis.
MTA3 functions as an essential scaffold within the NuRD complex, bridging the histone deacetylases HDAC1 and HDAC2 with chromatin-remodeling factors MBD3 and CHD4 to promote histone deacetylation and gene silencing. In germinal center B cells, MTA3 cooperates with the transcriptional repressor BCL6 to suppress key differentiation genes, most notably BLIMP1/PRDM1, thus maintaining the proliferative B-cell program. This transcriptional network is governed by upstream signals from estrogen receptor alpha (ER??) and PAX5, while MTA3 activity influences downstream targets including E-cadherin, Wnt-responsive genes, and MYC. Additionally, MTA3 physically interacts with NCOR1 and directly integrates BCL6-mediated repression at critical genomic loci.
In the Raji cell background, MTA3 disruption offers a powerful system to dissect the NuRD complex??s role in sustaining the oncogenic state of Burkitt lymphoma. Loss of MTA3 is predicted to alleviate BCL6-mediated repression of BLIMP1 and other plasma cell differentiation programs, potentially driving B-cell maturation or triggering growth arrest. This model therefore enables precise interrogation of how NuRD-dependent epigenetic silencing contributes to lymphoma cell survival, proliferation, and response to therapeutic agents targeting epigenetic regulators or B-cell receptor pathways.
Researchers can employ MTA3 Knockout Raji Polyclonal Cells to investigate germinal center B-cell differentiation, transcriptional repression by the NuRD complex, and B-cell lymphoma pathogenesis. Representative applications include chromatin immunoprecipitation to map MTA3 and BCL6 binding, co-immunoprecipitation of NuRD components, RT-qPCR analysis of BLIMP1 and BCL6 expression, and flow cytometry for B-cell surface markers. These cells are also suited for proliferation and apoptosis assays, drug sensitivity screens, and xenograft tumor models to evaluate tumorigenicity. For further details or technical support, please contact Ascent Research.
